Pharmaceutical company AbbVie is buying ImmunoGen in a deal valued at about $10.1 billion that will speed up its entry into the commercial market for ovarian cancer. ImmunoGen Inc. has the ovarian cancer treatment Elahere. AbbVie will pay $31.26 per share in cash for each ImmunoGen share. Both companies’ boards have approved the transaction, which is expected to close in the middle of 2024. It still needs approval from ImmunoGen shareholders.
